US SEC Trading Suspension Halt Orders — September 01, 2026

01-09-2026

XTI Aerospace received a Nasdaq deficiency notice on August 26, 2026 for failing to timely file its Q2 2026 Form 10-Q, due to an internal review of its former CEO who resigned on August 17, 2026. The company has 60 days (until October 26, 2026) to submit a compliance plan, and if accepted, Nasdaq may grant an exception until February 22, 2027. However, the company warns it may disclose substantial doubt about its ability to continue as a going concern, and there is no assurance it will regain compliance or maintain its listing.

• · The company expects the Form 10-Q to disclose substantial doubt about its ability to continue as a going concern.
• · The former CEO resigned on August 17, 2026, triggering the internal review.
• · The company has not yet estimated when the internal review or the Form 10-Q filing will be completed.
• · If Nasdaq does not accept the compliance plan, the company may appeal to a Nasdaq Hearings Panel.
• · The Notice has no immediate effect on the listing of the company's common stock on the Nasdaq Capital Market.

01-09-2026

BioXcel Therapeutics, Inc. (BTAI) filed an 8-K on September 1, 2026, disclosing that it has commenced Chapter 11 bankruptcy proceedings (the 'Cases') and is pursuing a sale transaction (the 'Transaction') under court supervision. The filing highlights significant risks including potential delisting, inability to continue as a going concern, and substantial uncertainty for common stockholders, who may receive little or no recovery. The company faces heightened administrative and legal costs, potential litigation, and risks of failing to obtain court approvals or complete the transaction.

• · The company is operating under Chapter 11 protection and requires court approval for motions filed in the Cases.
• · The company must comply with restrictions under its financing arrangements, including the DIP Facility.
• · The Chapter 11 process may result in common stockholders receiving no recovery.
• · The company faces risks of termination of the asset purchase agreement and potential adverse reactions from suppliers, vendors, partners, employees, and regulatory authorities.
• · The filing includes forward-looking statements and disclaims any obligation to update them.

01-09-2026

U.S. GoldMining Inc. received a Nasdaq notice on August 27, 2026, stating it no longer complies with audit committee independence requirements (Listing Rule 5605) following the resignation of board member Aleksandra Bukacheva, who also chaired the Audit Committee. The company has a cure period until the earlier of its next annual shareholders' meeting or August 14, 2027 (or February 10, 2027 if the meeting is held before that date) to regain compliance. The Board is actively searching for an independent director to fill the vacancy, and there is no immediate effect on the company's Nasdaq listing.

• · The resignation was effective August 14, 2026, and was not due to any disagreement with the company.
• · Nasdaq Listing Rule 5605(c)(2) requires the Audit Committee to have at least three independent directors.
• · The cure period extends to the earlier of the next annual shareholders' meeting or August 14, 2027, with an accelerated deadline of February 10, 2027 if the meeting occurs before that date.
• · The company is an emerging growth company as defined under SEC rules.

01-09-2026

Borealis Foods Inc. (BRLS) received a deficiency notice from Nasdaq on August 26, 2026, for failing to timely file its Q2 2026 Form 10-Q, violating Listing Rule 5250(c)(1). The company has until October 26, 2026, to submit a compliance plan, with a possible extension to February 16, 2027, if accepted. The delay is attributed to a review of accounting treatment for a Conversion Agreement requiring shareholder approval, but the notice has no immediate impact on trading.

• · The company's securities (Common Shares and Warrants) continue to trade on the Nasdaq Capital Market without immediate effect.
• · The compliance plan deadline is October 26, 2026; if accepted, Nasdaq may grant up to 180 calendar days from the Q2 2026 Form 10-Q due date, i.e., until February 16, 2027.
• · The filing delay is specifically due to a review of the accounting treatment for a previously disclosed Conversion Agreement, which requires shareholder approval under Nasdaq rules.

01-09-2026

Barinthus Biotherapeutics plc (BRNS) filed an 8-K on September 1, 2026, announcing that the High Court of Justice of England and Wales sanctioned the Scheme of Arrangement related to its merger with Clywedog Therapeutics, Inc. Trading of its American Depositary Shares (ADSs) on Nasdaq is expected to be halted prior to the opening of trading on September 9, 2026, with the Scheme expected to become effective on that date. The company's plans for delisting and deregistration of the ADSs remain unchanged.

• · The Merger Agreement was dated September 29, 2025, and involved Barinthus Biotherapeutics plc, Beacon Topco, Inc., Cdog Merger Sub, Inc., and Clywedog Therapeutics, Inc.
• · The Scheme of Arrangement and a capital reduction of the share premium account were sanctioned by the Court on September 1, 2026.
• · The Scheme is expected to become effective on September 9, 2026.
• · Trading of ADSs on Nasdaq is expected to be halted prior to the opening of trading on September 9, 2026.
• · The company is an emerging growth company as defined under the Securities Act.

01-09-2026

authID Inc. received a Nasdaq deficiency notice on August 27, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has a 180-day cure period until February 23, 2027, and may consider a reverse stock split. However, authID is also not in compliance with Nasdaq's stockholders' equity requirement, which could block access to a second compliance period and increase delisting risk.

• · The deficiency period ran from July 16, 2026 through August 26, 2026.
• · If the company does not regain compliance by February 23, 2027, it may be eligible for an additional 180-day compliance period, but only if it meets all other initial listing standards for the Nasdaq Capital Market, including the stockholders' equity requirement.
• · The company is already not in compliance with the stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)), as previously disclosed on August 21, 2026.
• · If authID is not eligible for a second compliance period or appears unable to cure the deficiency, Nasdaq will initiate delisting proceedings, subject to appeal to a Nasdaq Hearings Panel.

01-09-2026

CID HoldCo, Inc. (DAICW) received a third Nasdaq staff determination on August 27, 2026, for potential delisting due to failure to file its Form 10-Q for the period ended June 30, 2026. This adds to prior delisting bases for failing to meet the $50 million MVLS and $15 million MVPHS requirements. The company has requested a hearing and intends to seek an extended stay, but there is no assurance of continued listing.

• · The company has seven days from August 27, 2026 (until September 3, 2026) to request an extended stay of suspension pending the Hearings Panel's decision.
• · The hearing request regarding the delinquent filing stays suspension for 15 days from the date of request unless a further stay is granted.
• · The company's common stock remains listed on Nasdaq pending the outcome of the hearing.
• · The warrants (DAICW) are exercisable for one share of common stock at $287.50 per share, reflecting a reverse stock split effective May 29, 2026.

01-09-2026

IP Strategy Holdings, Inc. (IPST) received a Nasdaq notification on August 26, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2026, violating Nasdaq Listing Rule 5250(c)(1). The company has 60 days (until October 26, 2026) to submit a compliance plan, with a possible extension to February 22, 2027. The company intends to file the Form 10-Q and regain compliance in September 2026, but there is no guarantee of success, and failure could lead to delisting.

• · The Nasdaq notification has no immediate effect on the listing of the company's common stock.
• · If Nasdaq does not accept the compliance plan, the company may appeal to a Nasdaq Hearings Panel.
• · The company issued a press release on August 28, 2026, regarding the notification.